0001558370-24-000770.txt : 20240205 0001558370-24-000770.hdr.sgml : 20240205 20240205163105 ACCESSION NUMBER: 0001558370-24-000770 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240115 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240205 DATE AS OF CHANGE: 20240205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 24596164 BUSINESS ADDRESS: STREET 1: 701 LEE ROAD STREET 2: SUITE 103 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 484-324-7933 MAIL ADDRESS: STREET 1: 701 LEE ROAD STREET 2: SUITE 103 CITY: WAYNE STATE: PA ZIP: 19087 8-K/A 1 acrs-20240115x8ka.htm 8-K/A
0001557746false00015577462024-01-152024-01-15

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 8-K/A

(Amendment No. 1)

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): January 15, 2024

​

​

Aclaris Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

​

​

​

​

​

​

Delaware

​

001-37581

​

46-0571712

(State or other jurisdiction of incorporation)

​

(Commission File Number)

​

(IRS Employer
Identification No.)

​

700 Lee Road, Suite 103

Wayne, PA 19087

(Address of principal executive offices, including zip code)

​

(484) 324-7933

(Registrant’s telephone number, including area code)

​

N/A

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act: 

 

 

 

 

 

Title of Each Class:

 

Trading Symbol(s)

 

Name of Each Exchange on which Registered

Common Stock, $0.00001 par value

 

ACRS

 

The Nasdaq Stock Market, LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

EXPLANATORY NOTE

​

Aclaris Therapeutics, Inc. (the “Company”) is filing this Current Report on Form 8-K/A (Amendment No. 1) (the “8-K/A”) in order to amend its previously filed Current Report on Form 8-K, as filed with the Securities and Exchange Commission on January 19, 2024 (the “Initial 8-K”). The Initial 8-K was filed to disclose the appointment of Neal Walker as the Company’s Interim Chief Executive Officer and President (the “Interim CEO”). This 8-K/A amends Item 5.02 of the Initial 8-K in order to provide a description of the compensation agreement between the Company and Neal Walker that was previously omitted from the Initial 8-K as permitted by Instruction 2 of Item 5.02 of Form 8-K.

​

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

​

(b)Departure of Douglas Manion as Chief Executive Officer and President and Director

​

On January 15, 2024, the Company and Douglas Manion mutually agreed that Dr. Manion will step down as the Company’s Chief Executive Officer and President and resign from the Board of Directors (the “Board”), effective January 16, 2024. Dr. Manion’s resignation from the Board was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

​

(c)Appointment of Neal Walker as Interim Chief Executive Officer and President and Entry into Letter Agreement with Neal Walker

​

In connection with the departure of Dr. Manion, on January 15, 2024, the Board appointed Neal Walker as the Company’s Interim Chief Executive Officer and President, effective January 17, 2024. Dr. Walker will continue to serve as the Chair of the Board.

​

Biographical information about Dr. Walker is contained in the Company’s Definitive Proxy Statement for the Company’s 2023 Annual Meeting of Stockholders filed with the Securities and Exchange Commission on April 20, 2023 under the caption “Election of Directors” and is incorporated herein by reference. There are no arrangements or understandings between Dr. Walker and any other person pursuant to which he was selected as an officer of the Company, and there is no family relationship between Dr. Walker and any of the Company’s other directors or executive officers. There are no related party transactions between Dr. Walker and the Company that would require disclosure under Item 404(a) of Regulation S-K. Dr. Walker has previously entered into the Company’s standard form of indemnification agreement.

​

On January 31, 2024, in connection with Dr. Walker’s appointment as the Company’s Interim CEO, the Company and Dr. Walker entered into a letter agreement effective January 17, 2024 (the “Letter Agreement”) setting forth the terms of his employment. Pursuant to the Letter Agreement, Dr. Walker’s employment with the Company is temporary and may be terminated by the Board at any time. Dr. Walker will receive an annual base salary of $500,000 and will be eligible to receive a cash bonus equal to 60% of his base salary (pro rated based on time of service), subject to the achievement of performance goals established by the Board (the “Performance Goals”).

​

Dr. Walker was also granted a nonqualified stock option to purchase 497,000 shares of the Company’s common stock with an exercise price of $1.20 per share, which was the closing price of the Company’s common stock on the date of grant, and a restricted stock unit award for 142,000 shares of the Company’s common stock under the Company’s 2015 Equity Incentive Plan (the “2015 Plan”), each effective as of February 1, 2024. The option will vest and become exercisable, and the restricted stock units will vest, in equal monthly installments over 15 months subject to Dr. Walker’s Continuous Service (as defined in the 2015 Plan) as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service to the Company in any capacity, such awards will continue to vest in the event that the Board determines in its sole discretion that he achieved the Performance Goals prior to the cessation of his employment as Interim CEO. The equity awards will accelerate vesting and exercisability in full upon a Change in Control (as defined in the 2015 Plan). In addition, during the term of his employment as Interim CEO, Dr. Walker will not be eligible to receive compensation pursuant to the Company’s non-employee director compensation policy.

​

The foregoing description of the Letter Agreement is not complete and is qualified in its entirety by reference to the Letter Agreement, which the Company intends to file as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

​

​

​

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

  

​

​

​

​

ACLARIS THERAPEUTICS, INC.

​

​

​

​

By:

/s/ Kevin Balthaser

Date: February 5, 2024

​

Kevin Balthaser

​

​

Chief Financial Officer

​

​

​

​

​

​

​

 EX-101.SCH 2 acrs-20240115.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 acrs-20240115_lab.xml EX-101.LAB EX-101.PRE 4 acrs-20240115_pre.xml EX-101.PRE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Jan. 15, 2024
Document and Entity Information  
Document Type 8-K/A
Document Period End Date Jan. 15, 2024
Entity File Number 001-37581
Entity Registrant Name Aclaris Therapeutics, Inc.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-0571712
Entity Address, Address Line One 700 Lee Road
Entity Address, Adress Line Two Suite 103
Entity Address, City or Town Wayne
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19087
City Area Code 484
Local Phone Number 324-7933
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.00001 par value
Trading Symbol ACRS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001557746
Amendment Flag false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports acrs-20240115.xsd acrs-20240115_lab.xml acrs-20240115_pre.xml acrs-20240115x8ka.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "acrs-20240115x8ka.htm": { "nsprefix": "acrs", "nsuri": "http://www.aclaristx.com/20240115", "dts": { "schema": { "local": [ "acrs-20240115.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "acrs-20240115_lab.xml" ] }, "presentationLink": { "local": [ "acrs-20240115_pre.xml" ] }, "inline": { "local": [ "acrs-20240115x8ka.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_15_2024_To_1_15_2024_S58K1syzCUmp5jIDZtoI4w", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "acrs-20240115x8ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_15_2024_To_1_15_2024_S58K1syzCUmp5jIDZtoI4w", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "acrs-20240115x8ka.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Adress Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001558370-24-000770-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-000770-xbrl.zip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acrs-20240115x8ka_htm.xml IDEA: XBRL DOCUMENT 0001557746 2024-01-15 2024-01-15 0001557746 false 8-K/A 2024-01-15 Aclaris Therapeutics, Inc. DE 001-37581 46-0571712 700 Lee Road Suite 103 Wayne PA 19087 484 324-7933 false false false false Common Stock, $0.00001 par value ACRS NASDAQ false